Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 3300 of 3546 entries
View as:

Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01428531 Org: User:
Start: 01/31/12 End: 06/30/15 Due: 06/30/16

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

Phase: N/A Priority: Normal
NCT ID: NCT04376684 Org: User:
Start: 05/28/20 End: 08/16/21 Due: 08/16/22

Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)

Phase: N/A Priority: Normal
NCT ID: NCT00443053 Org: User:
Start: 03/31/07 End: 07/31/09 Due: 07/31/10

A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18

Phase: N/A Priority: Normal
NCT ID: NCT00500058 Org: User:
Start: 07/31/07 End: 03/04/10 Due: 03/04/11

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

Phase: N/A Priority: Normal
NCT ID: NCT00920218 Org: User:
Start: 07/14/09 End: 03/21/12 Due: 03/21/13

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.

Phase: N/A Priority: Normal
NCT ID: NCT00519376 Org: User:
Start: 08/31/07 End: 11/30/07 Due: 11/30/08

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02169583 Org: User:
Start: 06/12/14 End: 08/28/14 Due: 08/28/15

Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber

Phase: N/A Priority: Normal
NCT ID: NCT00404586 Org: User:
Start: 09/11/06 End: 01/16/07 Due: 01/16/08

A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT05131971 Org: User:
Start: 11/01/21 End: 10/12/23 Due: 10/12/24

GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00371488 Org: User:
Start: 04/06/06 End: 12/10/07 Due: 12/10/08

A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval

Phase: N/A Priority: Normal
NCT ID: NCT01328054 Org: User:
Start: 12/31/11 End: 03/31/15 Due: 03/31/16

Minocycline Bioequivalence Study

Phase: N/A Priority: Normal
NCT ID: NCT01938508 Org: User:
Start: 05/31/13 End: 06/30/13 Due: 06/30/14

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Phase: N/A Priority: Normal
NCT ID: NCT00345683 Org: User:
Start: 07/31/07 End: 11/30/08 Due: 11/30/09

Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration

Phase: N/A Priority: Normal
NCT ID: NCT00758264 Org: User:
Start: 10/30/08 End: 11/02/09 Due: 11/02/10

Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients

Phase: N/A Priority: Normal
NCT ID: NCT00686868 Org: User:
Start: 06/13/08 End: 05/02/11 Due: 05/02/12

An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT00057226 Org: User:
Start: 03/31/03 End: 04/30/04 Due: 04/30/05

Study Investigating Efficacy of an Occluding Dentifrice for Dentine Hypersensitivity

Phase: N/A Priority: Normal
NCT ID: NCT02705716 Org: User:
Start: 03/01/16 End: 05/20/16 Due: 05/20/17

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00359190 Org: User:
Start: 06/29/04 End: 01/09/08 Due: 01/09/09

The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain

Phase: N/A Priority: Normal
NCT ID: NCT00376454 Org: User:
Start: 11/30/02 End: 06/30/03 Due: 06/30/04

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT01406340 Org: User:
Start: 08/30/11 End: 08/31/13 Due: 08/31/14

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT02416232 Org: User:
Start: - End: - Due: -

Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Phase: N/A Priority: Normal
NCT ID: NCT01387178 Org: User:
Start: 07/31/08 End: 02/28/10 Due: 02/28/11

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02654145 Org: User:
Start: 03/17/16 End: 05/31/17 Due: 05/31/18

In Vivo Investigation of Initial Stages of Enamel Erosion

Phase: N/A Priority: Normal
NCT ID: NCT02533466 Org: User:
Start: 10/01/15 End: 11/06/15 Due: 11/06/16

Michelangelo - Oasis 5

Phase: N/A Priority: Normal
NCT ID: NCT00139815 Org: User:
Start: 04/30/03 End: 12/31/05 Due: 12/31/06